Reads

READS was our first engagement group and inspired our CEO to introduce other ideas. Our goal in READS is to choose engaging books related to business or healthcare that can spark some lively discussion.

2022

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

2021

Enanta Pharmaceuticals Announces Positive Data from Phase 1 Study of EDP-514 in Nucleos(t)ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection

Enanta Pharmaceuticals Announces Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus Core Inhibitor, in Viremic Chronic HBV Patients

Enanta Pharmaceuticals Adds COVID-19 to its Pipeline with the Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

2020

Enanta Pharmaceuticals’ HCV Collaboration Partner AbbVie Receives Marketing Authorization from the European Commission to Shorten MAVIRET® (glecaprevir/pibrentasvir) to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis

Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19